Ablacon, Inc. is a Wheat Ridge, CO-­­based company with offices in Munich, Germany and Menlo Park, CA, developing an advanced mapping system to guide the treatment of atrial fibrillation, the most frequent cardiac arrythmia. The company's system uses advanced algorithms and machine learning to precisely localize and characterize the sources of AF and to guide targeted therapy by visualizing the Electrographic Flow within the cardiac chambers. The company's technology obtained CE Mark in 2018 and is currently being used in Europe.